SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the market weighs potential near-term rate cuts against longer-term economic concerns and Japan bond yield surge. Community members are actively discussing whether the recent AI-driven rally is sustainable, pointing to specific levels and potential downside risks, while some are anticipating a year-end rally.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending amid discussions of potential catalysts like upcoming earnings and speculation around key figures like Roaring Kitty and Michael Burry. The community is actively dissecting trading patterns, potential gamma ramps, and the impact of large buy orders, while also eyeing the performance of GME warrants. Some traders express frustration with persistent price suppression despite positive fundamentals and potential short squeezes.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending amid discussions about its AI strategy, particularly the AWS re:Invent conference and new AI chip developments that are intended to compete with Nvidia. The community is weighing the potential impact of these innovations on Amazon's market position and profitability, along with its ongoing partnerships. Some are concerned over high spending and performance, while others express optimism about long-term cloud and AI growth.

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Polyrizon Ltd.

Polyrizon Ltd. Ordinary Shares

Polyrizon is trending due to positive preclinical data regarding its intranasal Naloxone hydrogel, with the community focusing on its potential as a multi-day runner and comparing it to other low-float Israeli stocks like $SMX. Discussions include potential price targets and the possibility of a short squeeze, while some traders are wary of potential dilution.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The Global X Dow 30 Covered Call ETF ($DJIA) is trending as investors weigh the impact of recent jobs data and potential Federal Reserve interest rate cuts. Community members are actively discussing resistance and support levels, with some anticipating a continued bullish trend while others warn of overbought conditions and an impending market correction. Hedge alerts are circulating, offering put options as protection against potential downturns.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending amid community discussions around its AI strategy and recent earnings expectations, with some questioning its ability to capitalize on AI, while others highlight its solid fundamentals. The stock's underperformance compared to its peers is also a key talking point, with some expressing concerns about the company's leadership. Upcoming earnings are a major catalyst, with potential for significant price movement based on the company's AI initiatives.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending amid discussions about its recent earnings beat and future prospects in the AI automation space; the community is weighing in on whether the company can sustain growth and capitalize on its partnerships with major tech players. Some traders are highlighting the high short interest and potential for a squeeze, while others focus on long-term potential and the stock's undervaluation relative to its peers. Discussions also include the upcoming fireside chat at the Barclays Global Technology Conference.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 2x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is trending as traders weigh market volatility amid economic data and global events. Community members are actively discussing potential market corrections, hedging strategies, and the impact of quantitative tightening. The upcoming reverse split is also a key point of discussion, with some traders expressing concerns about its impact on options.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as investors discuss upcoming catalysts, particularly the anticipated satellite launches in December. Community members are expressing excitement and speculating on potential price movements, while also debating the company's long-term potential in the space-based cellular broadband market. Bullish sentiment is fueled by the proximity to launch dates and the expectation of positive news.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

BRK.B is trending amid discussion of its massive cash reserves and strong Q3 earnings, with operating profits surging. Community chatter revolves around Berkshire's strategy given the current market conditions, particularly regarding potential acquisitions or share buybacks. Some investors view BRK.B as a safe haven during market uncertainty, while others question its valuation and future performance post-Buffett.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Buying: FibroGen (NASDAQ:FGEN) CEO Acquires 2,700 Shares of Stock

FibroGen, Inc (NASDAQ:FGEN - Get Free Report) CEO Thane Wettig bought 2,700 shares of the stock in a transaction on Monday, November 17th. The stock was purchased at an average cost of $9.10 per...

FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of +59.85% and -34.39%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

FibroGen, Inc. (FGEN) on Monday said that a Chinese regulator has approved the sale of its unit FibroGen International (Hong Kong) to AstraZeneca (AZN).FibroGen had announced the sale of its China unit to AstraZeneca for about $160 million in February. The closing of the transaction is now expected in the third quarter of 2025, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-approval-sale-fibrogen-china-astrazeneca">said</a>. &nbsp;The closing of the transaction remains subject to other contractual closing conditions and deliverables, the biopharmaceutical company added. The firm had previously expected the transaction to close by mid-2025. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/FGEN">FGEN</a> trended in the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.The company said earlier this year that it would repay its term loan facility to investment funds managed by Morgan Stanley Tactical Value following the closing of its transaction in a bid to simplify its capital structure. The transaction is further expected to extend the company’s cash runway into 2027, it added.Upon closing, AstraZeneca will obtain all rights to Roxadustat in China. Roxadustat is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients, irrespective of whether they are on dialysis.The company is currently considering a development plan for Roxadustat in anemia associated with lower-risk myelodysplastic syndrome in the U.S. Myelodysplastic syndromes (MDS) are a group of cancers where bone marrow doesn't produce enough healthy blood cells.FGEN stock is down by 28% this year but up by about 1% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-slips-under-116000-while-cardano-solana-lead-altcoin-selloff/chsO7iYRdQw">Bitcoin Slips Under $116,000 While Cardano, Solana Lead Altcoin Selloff</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mission Bay headquarters and sign for FibroGen, a biotechnology company producing recombinant gelatins for medical devices and pharmaceuticals, San Francisco, California, 2016. (Photo by Smith Collection/Gado/Getty Images).

Fibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZeneca

The company expects the transaction, which was announced in February, to close in the third quarter of 2025.

Equity

The company expects the transaction, which was announced in February, to close in the third quarter of 2025.


FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of -50.22% and -53.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates

FibroGen Executives Depart Amid U.S. Operations Overhaul

The latest update is out from FibroGen ( ($FGEN) ). FibroGen, Inc. is streamlining its U.S. operations with a significant cost reduction strategy...

Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments

Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments PR Newswire...

FibroGen Stock Is Surging After The Bell: What's Going On?

FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) FG-3165. The company also announced a new clinical...

Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates

Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates PR Newswire...

FibroGen Shares Climb On Strong Q1 Sales

FibroGen reported quarterly losses of 33 cents per share which missed the analyst consensus estimate of $(0.31) and represents a 59.26% increase year-over-year. Quarterly sales clocked in at $55.902...

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

Current Price	$8.12
Prev Close	$8.08
Open	$8.11
Dividend Yield	0.00%
50-Day Moving Average	$10.43
Beta	1.82
Avg. Volume	40,511.11
PE Ratio	0.20

52-Week High	$21.94
52-Week Low	$4.85
Market Capitalization	$32.69M
EPS (Annual)	-$11.89
Price to Book	-1.93
Revenue Per Employee	$131,648.89
Enterprise Value/EBITDA	N/A

FGEN
FibroGen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FGEN News

FGENFibroGen Inc